Company profile
Lakewood-Amedex Biotherapeutics Inc.
NASDAQ:LABTBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06020235 | phase2 | not_yet_recruiting | 2025-12-01 | 2026-06-01 | Lakewood-Amedex Inc | Nu-3 Gel for Infected Diabetic Foot Ulcers |
| NCT05276401 | phase2 | terminated | 2022-03-11 | 2022-05-18 | Lakewood-Amedex Inc | Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer |
| NCT07565506 | phase2 | recruiting | 2026-08-14 | 2027-01-01 | Lakewood-Amedex Inc | Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU |
| NCT02737722 | phase1_2 | completed | 2016-04-01 | 2017-08-01 | Lakewood-Amedex Inc | Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus |
FDA applications (0)
No records yet.